Starting Oral Terbinafine for Toenail Onychomycosis with Normal Liver Enzymes
Yes, it is safe to start oral terbinafine 250 mg daily for toenail fungus in this patient with normal baseline liver enzymes (AST 15, ALT 15 U/L), but baseline liver function tests must be documented before initiation and the patient must be counseled about specific adverse effects that require immediate discontinuation. 1, 2
Baseline Requirements Before Starting Treatment
Obtain and document baseline liver function tests (AST/ALT) and complete blood count before prescribing terbinafine. 3, 1, 2 This patient's normal values (AST 15, ALT 15) meet the safety threshold for initiation.
The FDA label explicitly states that "measurement of serum transaminases (ALT and AST) is advised for all patients before taking terbinafine tablets." 2
Baseline monitoring is particularly important in patients with history of heavy alcohol consumption, hepatitis, or hematological abnormalities, though not required in this case given normal baseline values. 3
Treatment Regimen
Prescribe terbinafine 250 mg orally once daily for 12–16 weeks for toenail onychomycosis. 3, 1, 2 The British Association of Dermatologists recommends the longer 16-week course for more extensive disease. 1
Terbinafine is the first-line treatment for dermatophyte onychomycosis based on superior efficacy compared to itraconazole, with mycological cure rates of 76% versus 38% at 72 weeks. 3
The optimal clinical effect occurs months after treatment completion due to the time required for healthy nail outgrowth. 2
Mandatory Patient Counseling on Adverse Effects Requiring Discontinuation
The patient must be counseled to immediately report and discontinue terbinafine if any of the following occur:
Hepatotoxicity symptoms: persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or pale stools. 2 While rare, liver failure leading to transplant or death has occurred with oral terbinafine. 2
Taste disturbance (dysgeusia): This can be severe, prolonged, or permanent. 3, 1, 2 Patients must understand this is not reversible in all cases.
Smell disturbance: Loss of smell may be prolonged or permanent. 2
Severe cutaneous reactions: Hives, mouth sores, blistering/peeling skin, swelling of face/lips/tongue/throat, difficulty swallowing or breathing (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome). 2
Depressive symptoms: Prescribers should be alert to development of depression during treatment. 2
Ongoing Monitoring Strategy
Re-evaluate the patient clinically 3–6 months after starting therapy to assess response and detect adverse effects. 1
Periodic liver enzyme monitoring is recommended during treatment, especially if the patient develops symptoms or has risk factors. 3, 1 In a 2023 retrospective study of 735 patients, 5.2% had elevated AST and 8.4% had elevated ALT at one month on terbinafine, but none discontinued treatment due to hepatotoxicity. 4
If neutrophil count drops to ≤1,000 cells/mm³, terbinafine must be discontinued. 2
Safety Profile in Context
Terbinafine is generally well tolerated, with adverse events reported in 10.5% of patients in post-marketing surveillance, most commonly gastrointestinal complaints. 5
In a large safety study of 1,508 patients, adverse events were reported in 44.7%, but only 7.8% were considered causally related to terbinafine. 6
Terbinafine is contraindicated only in patients with active or chronic liver disease. 3 This patient with normal liver enzymes does not have a contraindication.
Unlike azole antifungals, terbinafine has minimal drug-drug interactions, with the only significant interaction being with drugs metabolized by cytochrome P450 2D6. 3, 5
Additional Counseling Points
Advise the patient to minimize exposure to natural and artificial sunlight (tanning beds, UVA/B treatment) due to photosensitivity risk. 2
Counsel on preventive measures to reduce the 25% recurrence rate: avoid walking barefoot in public areas, use antifungal powders in footwear, and disinfect shoes and socks. 1, 7
Food intake does not affect terbinafine absorption, so it can be taken without regard to meals. 3